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In a double-blind study of influenza in a population of college students in 1984, ribavirin small-particle
aerosol treatment of 38 patients (18 treated, 20 control) infected with a new antigenic variant, influenza virus
strain A/Victoria/7/83 (H1N1), was associated with statistically significant reductions in the height and duration
of fever, systemic symptoms, and virus shedding. Patients received a total of 2.4 g of ribavirin over 42 h during
68 h of hospitalization without any side effects. In addition, in a study of patients infected with influenza virus
strain B/Texas/1/84 (seven treated, eight control) treated with ribavirin aerosol showed a trend of more rapid
recovery than control patients.
Ribavirin small-particle aerosol treatment of college stu-
dents with influenza infections has been shown to be effec-
tive against the two major influenza virus groups, A and B
(6, 7). In 1984, a mixed infection of influenza virus strain
B/Texas/1/84 and a new antigenic variant of influenza A,
strain A/Victoria/7/83 (HlNl), occurred in this population.
In this study, we report the results of a double-blind,
randomized evaluation of ribavirin small-particle aerosol
treatment of infection with these new variants. The findings
indicate a favorable response to treatment of influenza virus
strain A/Victoria/7/83 (H1N1) infection, but equivocal re-
sults were obtained with the small number of patients with
influenza virus strain B/Texas/1/84 infection who were treated
similarly.
MATERIALS AND METHODS
Patients. The patient population consisted of students ad-
mitted to the Beutel Health Care Center, Texas A & M
University, College Station, Tex. As in previous studies,
students were invited to participate in the study if they had
both an oral temperature of at least 38.3°C and systemic
symptoms of influenza that were of less than 24 h duration
(4a, 6, 7, 9). Diagnosis of influenza was based on the isolation
of virus from a nasal wash specimen.
In the 1984 study, a mixed outbreak of influenza occurred.
Of the 59 students enrolled in the study, 38 patients were
infected with influenza virus strain A/Victoria/7/83 (HlNl),
15 patients were infected with influenza virus strain
B/Texas/1/84, 1 patient was infected with influenza virus
strain A (H3N2) and 5 patients did not yield virus. Of the
patients infected with influenza virus strain A (HlNl), 18
were treated and 20 were used as controls, whereas 7 of
those infected with influenza B virus were treated and 8 were
used as controls.
Ribavirin small-particle aerosol treatment. The aerosol-pro-
ducing system was the same system described previously
(7), except that Aridyne 2000 Medical Air Compressors
manufactured by Timeter Instrument Corp. were used as the
source of compressed air. The aerosol contained an average
of 190 Fg of ribavirin per liter of air at a flow rate of 12.5
liter/min. The particles had a mass median diameter of 1.6
* Corresponding author.
,um; 95% of the particles had an aerodynamic mass median
diameter less than 5 ,um. Control subjects were treated with
an aerosol of sterile water.
Treatment was begun soon after the patient was admitted
and was continued for 16 to 18 h or until 8 a.m. the following
morning, whichever came first. The following morning all
participants were evaluated, and treatment was then re-
sumed in three, 4-h blocks for a total of 12 h per day.
Treatment was continued until 12 noon on day 3. The
ribavirin dosage was calculated as follows: the mean daily
minute volume (in cubic centimeters per minute per kilo-
gram) was calculated by multiplying the mean daily respira-
tory rate per minute by the mean tidal volume (5.43 ± 0.44
cm3/kg). Minute volumes (in liters) for each patient each day
were estimated by taking 0.19 mg (mean ribavirin aerosol
concentration per liter) times 60 min times the number of
hours of treatment each day times 0.7 (estimated fraction of
inhaled aerosol deposited in the respiratory tract).
Clinical assessment of illness. A detailed clinical assess-
ment of each patient was made on admission and daily at
8:00 a.m. and 4:00 p.m. thereafter until discharge. Patients
were examined in a separate examining room by physicians
who did not know their treatment status. Patients were not
informed of their treatment status until they were discharged
from the hospital. The nursing staff was not informed as to
the treatment status. At the conclusion of each examination,
the patient's illness was scored on a range of 0 to 3+ (most
severe) according to the categories of rhinitis, pharyngitis,
tracheobronchitis, pneumonia, and systemic illness. As in
previous studies, systemic illness, characterized by prostra-
tion, anorexia, headache, and muscle aches, was the most
prominent feature of the illness. Temperatures were mea-
sured orally every 4 h by the nursing staff. Patients were
considered afebrile when their temperatures returned to
sustained levels of less than 37.8°C. Antipyretics were not
routinely available; however, patients could receive acet-
aminophen (500 mg) for temperatures exceeding 39.7°C. A
greater number of patients with influenza A required acet-
aminophen in this study than in previous studies, reflecting
the increased severity of influenza illness associated with the
new antigenic variant. A total of 12 of 20 control and 6 of 18
treated patients received acetaminophen. Neither the pro-
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portion of patients nor the total dosage of drug received was
statistically significant between the two groups.
The following clinical chemical values were determined by
automated methodology on blood specimens obtained at
admission, at discharge, and 8 days and 1 month after
discharge: sodium, potassium, chloride, calcium, phospho-
rus, urea, creatinine, uric acid, cholesterol, triglycerides,
total protein, globulin, albumin, glucose, total bilirubin,
direct and indirect bilirubin, alkaline phosphatase, aspartate
aminotransaminase, alanine aminotransaminase, lactic dehy-
drogenase, and -y-glutamyl transaminase.
Hematologic studies consisted of the determination of
percent hematocrit, grams of hemoglobin, reticulocyte count,
leukocyte count with a differential cell count, and platelet
count. In addition, female patients in the study denied
having symptoms of early pregnancy and had negative
urinary screening tests for pregnancy.
Virus isolation, identification, and quantification. A nasal
wash specimen was collected on admission from every
patient who entered the study for virus identification and
was transported in veal infusion broth. In addition, for virus
quantification nasal wash specimens (lactated Ringers solu-
tion supplemented with veal infusion broth for storage at
-70°C) were taken on admission and twice daily thereafter
for 3 days. A follow-up nasal wash was obtained 7 to 10 days
later. A portion of the initial veal infusion broth sample was
inoculated into Madin-Darby canine kidney, rhesus monkey
continuous (designated as LLC), human epithelial carci-
noma (HEp-2), and human embryo fibroblast (WI-38) cell
cultures, and standard diagnostic procedures, including im-
munofluorescence, were used to identify individual subtypes
(1, 3). In addition, postinfection ferret antisera to selected
influenza B variants and a battery of mouse monoclonal
antibodies to the hemagglutinin of influenza B/Oregon/80
were used to finally identify the virus strain. Virus quantifi-
cation was performed in 24-well plates containing monolay-
ers of Madin-Darby canine kidney cells as previously de-
scribed (6). Virus titers, in 50% tissue culture infective doses
per milliliter of original nasal wash, were calculated by the
Karber method (8).
Hemagglutination-inhibition-antibody titration. Serum
specimens from acutely ill and convalescent patients were
titrated by standard methods as previously described for
hemagglutination-inhibition titers (2, 4). Five antigens,
A/England/333/80 (HlNl), A/Dunedin/6/83 (HlNl), A/Vic-
toria/7/83 (HlNl), B/Texas/1/84, and B/Singapore/222/79,
were used in the tests.
Analysis of patient data. Data analysis was performed with
the aid of the clinical information data management and
analysis system. P-values are based on analysis of these data
by the Wilcoxon rank sum or the Student t-test (two-tailed)
as indicated.
RESULTS
Infections with influenza virus strain A/Victoria/7/83
(HN1). Of the 54 patients infected with influenza virus, 38
were infected with the A/Victoria/7/83 strain. A total of 18
patients were treated with ribavirin aerosol, and 20 patients
were given sterile water aerosol as controls. There were 8
females (4 treated, 4 control) and 30 males (14 treated, 16
control); 2 treated and 7 control patients reportedly had been
vaccinated against influenza more than 24 months before
admission to this study. A total of 26 students reported
having had influenza, but there was no statistically signifi-
cant difference in the number or time of prior infection
between patients in either the treated or control group (P =
0.626). None of the differences in demographic parameters
was statistically significant.
Febrile response. Ribavirin small-particle aerosol treat-
ment reduced both the duration of fever (.37.80C) (Table 1)
and the mean maximum 12-h temperature. From the start of
treatment, fever persisted 18.7 h longer in control than in
treated patients (P = 0.004). At 24, 36, and 48 h after the
start of the treatment, patients receiving ribavirin aerosol
had statistically significant reductions in the mean maximum
temperature compared with control patients (P = 0.024,
0.015, and 0.004, respectively).
Quantification of virus shedding in nasal wash specimens.
Virus titers were determined on nasal wash specimens taken
at the time of admission and twice daily thereafter. Within 12
h from the start of treatment, mean virus titers in treated
patients were lower than on admission, whereas patients
receiving sterile water did not show any reduction in virus
titers until at least 24 to 36 h after admission (Fig. 1). The
reduction in virus concentration was statistically significant
between 12 and 48 h posttreatment (P = 0.001 to 0.048).
Systemic illness. Systemic illness, characterized by pros-
tration, anorexia, headache, and muscle aches, was the most
pronounced symptom and was reduced in treated as com-
pared with control patients by 24 h posttreatment (P =
0.054) (Table 2). This difference in systemic illness scores
persisted through 36 h. Rhinitis, pharyngitis, and tracheo-
bronchitis were never severe in either group of patients.
Influenza antibody titers. Of the 38 patients with influenza
identified by virus isolation, 37 demonstrated a fourfold or
greater rise in antibody titer in serum to the new antigenic
type A/Victoria/7/83, whereas only 30 demonstrated a rise to
the previously circulating antigen A/England/333/80 (P =
0.012; chi-square analysis). The geometric mean antibody
titers for either acute or convalescent sera were not different
for either antigen in treated or control patients (Table 3).
However, there was a statistically significant greater fold
rise in antibody titer with the A/Victoria/7/83 antigen (P =
0.005; the Wilcoxon rank sum test, two-tailed).
Ribavirin aerosol dosage. Individual daily treatment peri-
ods were similar in treated and control patients with a total
of about 42 h (Table 4). The 18 patients treated with ribavirin
received a total of 2.4 g of drug during their 41.9 h of
treatment over the 3 to 4 days of treatment. This dosage of
ribavirin can be calculated to have a mean concentration of
34.9 mg/kg or 0.83 mg/kg per h of treatment. There was no
toxicity observed.
Hematological findings. A slight but significant increase in
hematocrit was seen in both treated and control patients at
the time of discharge from the hospital as compared with
TABLE 1. Timing of events in patients with influenza virus strain
A/Victoria/7/83 (H1N1) infections
Time (h + SEM) for the
following patients:
Event P value"
Treated Control
(18)a (20)a
Onset of systemic illness to:
Admission 17.8 ± 1.3 15.4 ± 1.3 0.209
Start of Treatment 19.0 ± 1.3 16.5 ± 1.3 0.171
Afebrile (<37.8°C) 49.0 ± 4.8 65.2 ± 3.8 0.011
Discharge 85.6 ± 2.1 83.8 ± 1.8 0.3
Start of treatment to 29.9 ± 5.0 48.6 ± 3.8 0.004
afebrile state
a Number of patients is indicated in parentheses.
b The Student t test, two tailed.
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HOURS POST-TREATMENT
FIG. 1. Mean virus titers at 12-h intervals from the start of
treatment in patients infected with influenza virus strain A/Vic-
toria/7/83 (HlNl). At 0, 12, 24, 36, 48, 60, and 72 h, P values (the
Student t test, two-tailed) were 0.120, 0.048, 0.001, 0.009, 0.007,
0.129, -0.3, respectively. Symbols: 0, control patients; A, treated
patients. TCID", 50% tissue culture infective dose.
mean values at admission and at 1 week and 1 month after
admission (Fig. 2). The total leukocyte count in treated and
control patients was about 7,000/mm3 at admission and
dropped significantly (P < 0.02) at the time of discharge
about 3 days later. The reduction in counts was greatest
among- control patients. Thereafter, the counts returned to
normal values. Changes in total leukocyte counts were
principally contributed by a major decline in the number of
polymorphonuclear cells, which was greatest among control
patients (P = 0.06). In treated patients, these counts re-
turned to normal in 1 week. Values in control patients
remained low at 1 week (treated versus control; P = 0.03).
At 1 month, treated and control values were similar. Not
shown was a significant reduction in reticulocyte counts,
which was from about 1.2% in treated and control patients at
admission to about 0.8% at the time of discharge from the
hospital. These counts returned to normal ranges by 1 month
after admission. Platelet counts did not show significant
fluctuations in treated or control patients.
Influenza virus strain B/Texas/1/84 infection. Of the 54
patients with influenza infection, 15 had influenza B virus
TABLE 2. Mean systemic symptom score based on 12 h intervals
from start of treatment in patients with influenza virus strain
A/Victoria/7/83 (HlNl) infection
Range of severitya at the following times (h) post
Patient (no.) treatment:
and P value
0 12 24 36 48 60 72
Treated (18) 2.8 2.6 1.8 1.4 1.1 0.9 0.6
Control (20) 2.8 2.6 2.3 2.1 1.6 1.2 0.4
P valueb 0.878 0.839 0.054 0.052 0.095 0.269 0.639
a Range of severity: 0 to 3+ (severe).
b The Wilcoxon rank sum test, two-tailed.
TABLE 3. Geometric mean serum hemagglutination-inhibition
antibody titers in serum to influenza virus strains A/England/333/
80 (H1N1) and A/Victoria/7/83 (HlNl)
Geometric mean titer of antibody to the following strains
in the indicated stages of illness:
Patient (no)
and P value A/England/333/80 (HlNl) A/Victoria/7/83 (HlNl)
Acute Convalescent Acute Convalescent
Treated (18) 4.2 37.3 (8.9)a 4.2 94.4 (22.3)
Control (20) 4.5 32.0 (7.1) 4.3 78.8 (18.3)
P valueb 0.882 0.788 0.973 0.630
a Fold rise in geometric mean antibody titer is indicated in parentheses.
b The Wilcoxon rank sum test, two-tailed.
isolated from their initial nasal wash specimen. In this small
group (seven control, eight treated), the time from the onset
of systemic illness to the start of treatment was more than 5
h longer in control than in treated patients (20.5 + 2.2, 15.4
+ 2.1 h, respectively). The time of onset of systemic illness
or from the start of treatment to a sustained temperature of
less than 37.8°C (i.e., afebrile) was less in treated patients(16.1 versus 11.0 h, respectively), but the differences were
not significant. In addition, the number of patients with a
duration of fever greater than 50 h was seven of seven
patients for the control group and only four of eight patients
for the treated group (P = 0.077; the Fisher exact test).
These results, along with the reduced mean maximum tem-
perature of treated patients at 24 h posttreatment (P =
0.065), suggest a therapeutic effect for ribavirin aerosol in
this group.
Hematological changes in influenza B patients closely
resembled those described for patients infected with influ-
enza virus strain ANVictoria/7/83 (HlNl). Specifically, poly-
morphonuclear cell counts diminished from admission to
discharge, whereas lymphocyte counts increased in this
interval and returned to normal ranges by 1 month after
admission. The reduction of reticulocyte counts at discharge
was similar in degree to that in patients infected with
influenza virus strain A/Victoria/7/83 (HlNl) (data not
shown).
Clinical chemical findings in patients infected with influenza
viruses A and B. Among 23 clinical chemical tests performed
during and after illness, there were no significant differences
between treated and control patients. Specifically, bilirubin
and liver enzymes tests did not vary from normal in treated
and control patients.
DISCUSSION
The present study has shown a consistent and substantial
therapeutic effect of ribavirin aerosol in the treatment of
infection caused by a new variant of influenza virus, strain
A/Victoria/7/83 (HlNl). Previous studies have shown that
ribavirin is active in the treatment of infections caused by
TABLE 4. Mean ribavirin dosage in treated patients infected with
influenza A virus
Ribavirin dosage Mean time No. of
Day mg/day mg/kg/day treated (h) patients
0 543 7.8 8.3 18
1 1011 14.8 17.9 18
2 647 9.5 11.9 18
3 189 2.8 3.8 2
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FIG. 2. Mean hematocrit and leukocyte (WBC) absolute counts
in treated and control patients with influenza virus strain
A/Victoria/7/83 (HlNl) infection. In addition to probabilities of
differences between treated and control patients indicated on the
figure, the wide variations at different time periods within treated
and control groups were highly significant (P < 0.01). For example,
the drop in absolute polymorphonuclear (Polys) cell counts from
admission to discharge in treated patients was highly significant (P
= 0.001), and the increase in polymorphonuclear cell counts in
treated patients from discharge to 1 week was highly significant (P =
0.01). Open symbols represent control patients; closed symbols
represent treated patients.
influenza virus strains AIEngland/333/80 (HlNl) in 1981 (6)
and 1982 (9), influenza virus strain A/Bangkok/l/79 (H3N2)
in 1983 (4a), and influenza virus strain B/Singapore/22279 in
1982 (7). A trend of therapeutic effect was also seen in 1984
in a study of a small number of cases of infection with
influenza virus strain B/Texas/1/84. No effect was observed
in a study of disease caused by infection with influenza virus
strain A/England/333/80 (HlNl) in 1983 (Smith et al., ed.,
Clinical Aspects of Ribavirin, in press).
The influenza virus strain A (HlNl) disease encountered
in the past 4 years has been a mild illness, with fever
occurring in control patients receiving sterile water aerosol,
persisting for an average of 40 h from the start of treatment.
The period from the onset of illness to the start of treatment
averaged about 15 h in all groups. Fever in treated patients
persisted 28 h from the start of treatment. However, in the
1983 study (4a), in which no effect was detected, duration of
fever from the start of treatment was 30.3 and 33.5 h in
treated and control patients, respectively. When the studies
with positive results only were considered, it was found that
fever in control patients (start of treatment to afebrile state)
persisted for an average of 42 h, whereas it lasted for only
27.5 h in treated patients. Thus, with the temperatures of
patients available in these studies, it can be determined that
a difference of about 15 h in the duration of fever between
treated and control patients will be required for a therapeutic
effect to be demonstrated. In the present study this result
was achieved. In 1981, this result was achieved because
treated patients had fever for only 21 h, whereas in control
patients, fever lasted for 35.5 h.
This degree of variation in duration of fever between
treated and control patients may be consistent with the
concept that we have observed a fairly uniform type of
illness from year to year. In support of this is the finding that
the duration of fever from start of treatment in influenza
virus strains A/Bangkok/l/79 (H3N2) and B/Singapore/222/79
infections lasted 55 h in control patients (4a, 7). The use of
duration of fever as a measure of severity seems justified
because virus shedding patterns and symptomatology also
correlated with this index.
The polymorphonuclear cell counts in treated and control
patients with influenza virus strain A/Victoria/7/83 (HlNl)
infection can also be interpreted to indicate a therapeutic
effect of ribavirin aerosol. The counts in treated patients
dropped less during treatment than they did in controls,
suggesting that treatment minimized the suppressive effect
of influenza virus infection on these cells. At 1 week after
admission the polymorphonuclear cell counts of treated
patients were essentially normal, whereas counts in control
patients remained low (P = 0.03). Total leukocyte counts
also reflected these differences. Changes in the other leuko-
cyte count series were similar in treated and control pa-
tients.
The percent hematocrit in treated and control patients was
increased significantly at discharge over the value at admis-
sion and the values at 1 week and 1 month after admission.
This increase may have been due to the nearly continuous
use of a face mask in treated and control patients which
interfered with the oral intake of fluids. Other explanations
should also be sought for this finding because it could also
represent dehydration as a consequence of infection, even
though it occurred during a time when defervescence and
recovery was occurring and oral intake was unrestricted.
A significant reduction in the percentage of circulating
reticulocytes was noted in an earlier study (6), and this
difference was again observed. The change occurred in both
treated and control patients. Changes in blood counts of
patients with influenza virus B were similar to those with
influenza virus A infection.
As in previous studies, there was no laboratory or clinical
evidence of toxicity of ribavirin small-particle aerosol. The
present report thus extends the findings of the safety and
therapeutic effectiveness of ribavirin aerosol in the treat-
ment of infections caused by influenza viruses A/Victoria!
7/83 (HlNl) and B/Texas/1/84.
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